Novo’s Wegovy Prevents Heart Attacks at a Cost
It may cost insurers more than $1 million to prevent one heart attack with Wegovy
Photo: Steffen Trumpf/dpa (Photo by Steffen Trumpf/picture alliance via Getty Images)
Hi, it’s Bob in New York. Doctors are excited because Novo Nordisk’s obesity drug Wegovy was shown to prevent heart attacks in a new trial. But it’s going to be very expensive, according to a new analysis. First...
When Novo Nordisk announced recently that its obesity drug Wegovy slashed the rates of heart attacks and strokes by 20% in patients with preexisting cardiovascular disease, it was hailed as a milestone that could lead to broader insurance coverage for the injectable medication.